Pretzel Therapeutics, a Boston, MA-based firm biotechnology firm creating therapies for POLG and mtDNA depletion associated mitochondrial illnesses, acquired an funding from Mito Funds.
The quantity of the deal was not disclosed.
The corporate intends to make use of the funds to develop operations and R&D efforts.
Pretzel Therapeutics offers the PX578, its bioenergetics portfolio’s lead improvement program, lately entered Section 1 medical improvement within the U.S. The remedy’s focus is restoring perform to mutant mitochondrial DNA polymerases, permitting repopulation of depleted mtDNA, and providing a promising strategy for the remedy of mitochondrial DNA polymerase issues (generally often called POLG issues) and different extreme situations linked to mtDNA depletion.
The corporate has analysis services in Mölndal , Sweden, centered on harnessing mobile energetics to modulate illness processes and enhance survival, perform and high quality of life for a breadth of situations.
FinSMEs
14/07/2025
